

26 February 2024

Oncimmune Holdings plc
("Oncimmune" or the "Company")

Results of Annual General Meeting

Oncimmune Holdings plc (AIM: ONC.L), a leading autoantibody profiling company to the pharmaceutical and biotechnology industry, announces that at the Company's Annual General Meeting held earlier today all resolutions were duly passed.

The Notice of Annual General Meeting containing the full text of all of the resolutions is available on the Company's website at www.oncimmune.com, the results of the proxy vote on each of the resolutions will also be made available on the Company's website shortly.

The Company will be holding a general meeting to, amongst other things, receive the Company's annual report for year ended 31 August 2023 ("FY23") and to approve the report on Directors' remuneration for FY23. A further announcement setting out details of this general meeting will be made in due course.

Oncimmune Holdings plc
contact@oncimmune.com

Singer Capital Markets (Nominated Adviser and Broker)
Philip Davies, Harry Gooden, James Fischer
+44 (0)20 7496 3000

Zeus (Joint Broker)
Dominic King, Victoria Ayton, Dan Bate
+44 (0)20 3829 5000
+44 (0)20 3727 1000

About Oncimmune

Oncimmune is a precision medicine company, specialising in analysing immune interactions through the autoantibody profile. Taking a platform approach to generating insights, Oncimmune is partnering with global pharmaceutical and biotech companies, as well as contract research organisations (CROs) to discover novel biomarkers for the development of more targeted and effective therapies across many immune-mediated diseases. Our mission at Oncimmune is to enable precision medicine. We help our partners to discover novel biomarkers, drug targets and predict treatment efficacy through the application of our platform. We are able to do this by deploying our world class scientific team and our cutting-edge technology platform, built on years of experience in the field. Our aim is to make this an essential tool in drug discovery and development.

Oncimmune is headquartered in the UK, with its discovery and development facility based in Dortmund, Germany and a business development team based in the US and Europe.

For more information, visit www.oncimmune.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact ms@seg.com or visit www.ms.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

RAGQKABBDBKDPBB